Neuronal Nicotinic Receptors - April 2008
Providing a monthly detailed view and analysis of all key information from the exciting and rapidly expanding field of neuronal nicotinic receptors, UpdatesPlus-Nicotinic Receptors is a must for all involved in CNS drug development. UpdatesPlus is available as a yearly subscription and covers up to date analysis of journal articles; new clinical trials; company presentation and patents. See December 2007 edition now (free sample copy)
What's in the April 2008 edition of UpdatesPlus-Nicotinic Receptors?
-
Disappointing data on CoMentis’ GTS-21 - Is attention about to shift to second generation pipeline candidate?
-
En Vivo Pharmaceuticals' new schizophrenia biomarker study of EVP-6124
-
Pfizer's evolving Chantix/Champix strategy
-
Abbott continue development of ABT-089
-
Lilly to develop α4ß2 ligands with a similar profile to Targacept’s TC-5214?
-
Recent Neurosearch patent hints at new approach to nicotinic receptor modulation
-
Targacept report on new molecules with low nanomolar affinity at both α4ß2 and α7 receptors
Full and up to date pipeline
Pricing & Delivery: UpdatesPlus is available on a subscription basis. A one-off payment will get you the next twelve monthly editions of UpdatesPlus-Nicotinic Receptors plus access to all past editions. UpdatesPlus is available for unlimited use within your company. Delivered in a powerpoint format, UpdatesPlus is both easy to use and also ready for use within a presentation setting
2008 issues:
About UpdatesPlus: Through DailyUpdates, LeadDiscovery has access to one of the most comprehensive sources of information for the drug development sector. UpdatesPlus takes this information and uses our industrial experience to provide a monthly analysis of breaking activity in selected indications and molecular targets. If this is the first time that you have heard of UpdatesPlus please take a moment to have a look at an example. If you would find such a service of use in your area contact us now.
Other users found this report page using the following search terms: Neuronal Nicotinic Receptors nicotinic receptors alzheimer's amyloid depression alpha7 alpha6 alpha4beta2 evp6124 nicotinic receptors company lilly pharmaceutical ligands biomarker made envivo
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.